Pharma's growing recognition of the strategic importance of the microbiome in drug discovery as well as its alignment with the company's approach to development paved a path for Second Genome Inc. to close a $42.6 million series B round co-led by Pfizer Venture Investments and Roche Venture Fund, Peter DiLaura, Second Genome's president and CEO, told BioWorld Today.